Primary Immune Thrombocytopenia (ITP): Quality of Life Impaired by Prolonged Use of Corticosteroids

During the event “Primary Immune Thrombocytopenia: changing the approach to change life”, promoted by Inrete with the non-conditioning contribution of Novartis, the study “Analysis of the epidemiology and drug use of patients suffering from primary immune thrombocytopenia in Italian contexts “, conducted by CliCon Srl. The round table also offered the opportunity to illustrate the results of the international study” iWISh “which photographs the negative impact on patients’ quality of life also linked to prolonged therapy with corticosteroids.

!function(f,b,e,v,n,t,s)
{if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};
if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′;
n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];
s.parentNode.insertBefore(t,s)}(window, document,’script’,
‘https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘415374439673532’);
fbq(‘track’, ‘PageView’);